Chronic, recurrent Lymphocytic Leukemia Active Not Recruiting Phase 1 Trials for Ibrutinib (DB09053)

Also known as: Recurrent Chronic Lymphocytic Leukemia

IndicationStatusPhase
DBCOND0112002 (Chronic, recurrent Lymphocytic Leukemia)Active Not Recruiting1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01886859Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaTreatment
NCT02160015Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by SurgeryTreatment